The invention relates to a patch (2) with at least one filler and at least one active ingredient, wherein the local distribution of the active ingredient or ingredients within the patch (2) takes place dependent on the morphology, anatomy and physiology of the lesion (1) to be treated.

A light emitting device array includes a substrate, a heat sink disposed on the substrate, at least two light emitting devices disposed on the heat sink and spaced apart from each other, a connector disposed on the light emitting device and configured to apply power, an insulating layer interposed between the heat sink and the connector, a fixing member configured to support a position of the light emitting device, on the light emitting device, and an adhesive layer provided on the fixing member to make contact with a skin.

A source of light energy such as a source of violet light energy is coupled to a structure configured to contact the eye. The light source and structure are arranged to provide therapeutic amounts of violet light energy to the eye in order to inhibit the progression of refractive error such as myopia. The light source can be configured in many ways and may comprise a radioisotope and a phosphorescent material. The structure configured to contact the eye may comprise a contact lens or an implant.

A flexible brachytherapy device includes a bioresorbable carrier matrix structure comprising a plurality of radio-isotope particles and having opposite first surface and second surfaces. The bioresorbable carrier matrix structure degrades, when implanted at a wound site, at a rate substantially longer than a half-life of the plurality of radio-isotope particles. A hydrophilic substrate located adjacent to the first surface of the bioresorbable carrier matrix structure degrades, when implanted at the wound site, at a rate shorter than the bioresorbable carrier matrix structure to prevent migration of the device during the half-life of the plurality of radio-isotope particles. A hydrogel substrate located adjacent to the second surface of the bioresorbable carrier matrix structure shields radioactivity and degrades at a rate longer than the half-life of the plurality of radio-isotope particles.

A radiation dermatitis prevention apparatus includes: a pack (10), including: a pocket (12) including a face panel (16) and a back panel (18), wherein the panels (16, 18) are secured to each other along their respective peripheries in such a way as to define an opening (20), wherein the face panel (16) is constructed from a material suitable for contact with a patients skin and which readily permits fluid to flow through its thickness; and an insert (14) sized to fit in the opening (20) and made of a material which is suitable for holding and releasing a radiation cream in viscous fluid form.

A novel treatment method is disclosed, wherein a patch configured to be placed on a patient's skin is activated, before placement, to deliver localized radiotherapy to a diseased area of the skin. The disclosed devices and methods minimize or prevent collateral damage to the neighboring tissues. In most cases, the disclosed devices and methods include coating a contoured, solid, flexible or conformal substrate with one or more lanthanide elements and then activating (e.g. neutron irradiation) the elements such that its resulting radioisotope emits beta-particles into the diseased skin surface when applied to the patient's skin. Novel processes are described for fabricating and irradiating the lanthanide-based skin patch, for example a holmium-based skin patch.

The invention relates to a patch (2) with at least one filler and at least one active ingredient, wherein the local distribution of the active ingredient or ingredients within the patch (2) takes place dependent on the morphology, anatomy and physiology of the lesion (1) to be treated.

Provided is a process of producing activated particles comprising .sup.188Re-isotopes and/or .sup.186Re-isotopes by irradiating non-volatile and water-insoluble starting particles comprising a rhenium compound with neutrons. Further provided is a process of producing corresponding non-volatile and water-insoluble starting particles. Further provided are respective starting particles and activated particles, respectively, and a composition comprising a plurality of activated particles. The activated particles, and the composition comprising same are suitable for use in radionuclide therapy, and for cosmetic applications.

Disclosed is a layer structure for epidermal radionuclide therapy (brachytherapy) of a patient comprising, from a patient's view, a proximal adherent layer for applying the layer structure on the skin surface to be treated of a patient; a flexible, transparent carrier layer that from a patient's view is located in a distal direction on the adherent layer; and at least one radionuclide-containing emission layer located on the carrier layer, the adherent layer and the carrier layer with regard to their components and thickness being formed such that they are essentially transparent for and radiation. The layer structure is suited particularly for radiotherapeutic treatment of the basal-cell carcinoma (BCC) and the squamous cell carcinoma (SCC). With the aid of the layer structure, geometrically complex skin lesions caused by a tumor, as occurring e.g. on the outer edge of the auricle, may be treated easily.

Radiation therapy devices, systems and methods are in general sheet-like form, are characterized by flexibility, and include at least one spacer that can be a balloon or bubble that assists in placement of radio therapeutic members at desired treatment locations along or around a limb, within an existing body cavity, or at a site that was formed under a patient's skin for treatment purposes. Sarcoma treatment is particularly conducive to treatment by these devices, systems and methods. One or more detectors, such as microdiodes, are accommodated when desired on the device, and a hyperthermia tube or the like is also includable that delivers hyperthermia treatment for the target treatment site or sites. Data collected by the detector allows the medical professional to monitor radiation treatment and, when desired, interaction between hyperthermia treatment and radiation delivery by the radiation treatment member.